Hillard M Lazarus, MD, FACP is an expert in Hematology at University Hospitals of Cleveland (United States). As of October 2026, ScienceLeadR ranks Hillard M Lazarus in the top 1% of experts worldwide for Bone Marrow Transplantation, Cell Transplantation and Tissue Transplantation. Hillard M Lazarus has authored 1,190 publications, the most recent in 2026, and is an investigator in 24 clinical trials. SLR score: 2,970 (community average: 125). How the SLR is computed.

LeadR Profile

Hillard M Lazarus, MD, FACP University Hospitals of Cleveland United States
2 970 ScienceLeadR Reputation 2970
Network Map

Hematology

Subspecialties: Transplantation - Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Hillard M Lazarus, MD, FACP is Professor of Medicine at Case Western Reserve

University (CWRU) with five (5) decades of experience in clinical and translational

research. For nearly 40 years he has been a national and international leader in the

field of hematologic malignancies and blood and marrow transplantation as well as

a mentor to countless junior colleagues influencing many to pursue academic medicine

careers. He was first chair of the Blood and Marrow Transplant Committee of the

National Cancer Institute (NCI)-funded Eastern Cooperative Oncology Group (ECOG), a

position he held for 17 years; he was Co-Chair of the Lymphoma Committee of the

Center for International Blood and Marrow Transplantation Research (CIBMTR) for 19

years. As Principal Investigator of the Case Consortium for 17 years, he led one of the

original Core Centers of the Blood and Marrow Transplant Clinical Trials Network

(BMT CTN), an organization funded by the NCI and the National Heart, Lung and Blood

Institute (NHLBI). Dr. Lazarus has been recognized for research in mesenchymal stem

cell transplantation, autologous hematopoietic cell transplantation for lymphoma, and

allogeneic hematopoietic cell transplantation for malignancies. He helped develop many

new anti-cancer therapies and sophisticated supportive care technologies including

several antimicrobial therapies. He was inducted into the American Cancer Society

Cancer Care Hall of Fame and he received their Lifetime Achievement Research Award

(2007). Dr. Lazarus was awarded the Alumni Lifetime (Distinguished) Achievement

Award by Carnegie Mellon University (2011); Leukemia and Lymphoma Society 2011

Man of the Year (Northern Ohio); and Honorary Alumnus of the Year Award (2013) at

CWRU School of Medicine. He also held the George & Edith Richman Professor &

Distinguished Scientist in Cancer Research endowed chair. His research has been

published in over 800 original, peer-reviewed manuscripts and he is the editor of ten

(10) textbooks. He is Editor-in-Chief of Blood Reviews. He previously was Editor-in-

Chief of two (2) high-impact journals, Bone Marrow Transplantation as well as

Best Practice & Research Clinical Haematology. Currently, Dr. Lazarus’ research generates

a D-Index score of 121 in the discipline of Medicine, based on 62,936 citations,

with a national ranking of 1,483 and world ranking of 2,589 (https://research.com/u/hillard-m-lazarus).

Organizations

Career arc: 1983 - 2026

Source: PubMed

University Hospitals of Cleveland

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1190

Citations

Citations: 64 518 1st author: 135 Last author: 202 Unique author: 19


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study.
PMID 42832396 — cells, precursor cell lymphoblastic leukemia-lymphoma, leukemia, drug therapy, therapeutics, enhancer elements, genetic, mutation, chemotherapy
Blood20260
Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.
PMID 42687832 — bone marrow, hematology, leukemia, biopsy, leukemia, myeloid, acute, leukemia, myeloid, therapeutics
Haematologica20260
Jargon redux.
PMID 42185648
Bone Marrow Transplant20260
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.
PMID 41890705 — clofarabine, cytarabine, leukemia, leukemia, myeloid, acute, aged, leukemia, myeloid, therapeutics
Blood Neoplasia20260
ATRA treatment in the emergency department is associated with reduced early mortality in acute promyelocytic leukemia-a real-world multicenter retrospective cohort analysis.
PMID 41631884 — mortality, hemorrhage, leukemia, promyelocytic, acute, emergencies, lymphoma, neoplasms, leukemia, leukemia, lymphoid, therapeutics, emergency service, hospital, tretinoin
Leuk Lymphoma20260

Clinical Studies 24

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 3

By phase:

Phase 3 10
Phase 2 6
Phase 1 3
Phase 1/Phase 2 3
N/A 2

By status:

Completed 16
Active not recruiting 4
Recruiting 1
Terminated 1
Unknown 1
Withdrawn 1

By type:

Interventional 22
Observational 2

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 1
multicentric5to9 1
multicentricup10 16

Main Topics

LeadR Networks

Main global connection map